Last reviewed · How we verify
NCT03691766
Photobiomodulation Therapy in Persons With Multiple Sclerosis
NA trial testing Photobiomodulation Therapy in Multiple Sclerosis, Relapsing-Remitting in 21 participants. Completed in 23 September 2019.
23 September 2019
Quick facts
| Lead sponsor | Marquette University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | supportive care |
| Enrollment | 21 |
| Start date | 30 April 2018 |
| Primary completion | 23 September 2019 |
| Estimated completion | 23 September 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Photobiomodulation Therapy
- Placebo
Conditions studied
- Multiple Sclerosis, Relapsing-Remitting — all drugs for Multiple Sclerosis, Relapsing-Remitting →
Sponsor
Marquette University
Who can join
Adults 20 to 60, any sex, with Multiple Sclerosis, Relapsing-Remitting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03691766
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Photobiomodulation Therapy
Trials testing the same drug.
- NCT05561803 — The Use of Photobiomodulation in the Management of Radiodermatitis in Patients in Palliative Care. A Prospective Study. · withdrawn
- NCT06122116 — Investigating Orthobiologics After PRP and Photobiomodulation for Knee Osteoarthritis · NA · terminated
- NCT05760092 — The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial. · Phase 2 · completed
- NCT05751785 — Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy · NA · completed
- NCT05557825 — The Use of Photobiomodulation in the Management of Radiodermatitis in Head and Neck Cancer Patients · completed
Other recruiting trials for Multiple Sclerosis, Relapsing-Remitting
Currently open trials in the same condition.
- NCT06408259 — Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relap · Phase 3 · recruiting
- NCT06569550 — Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis · NA · recruiting
- NCT06389968 — Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis · NA · recruiting
- NCT06345157 — ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients · active not recruiting
- NCT06715436 — Multiple Sclerosis and the Effects of Ketogenic Diet Therapy · NA · recruiting
Other Marquette University trials
Trials by the same sponsor.
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT06624982 — Determinants of Bone Dimensional Changes After Extraction and Alveolar Ridge Preservation · recruiting
- NCT06858293 — Mental Imagery to Improve Quadriceps Strength Post Anterior Cruciate Ligament Reconstruction: a Feasibility Study · NA · recruiting
- NCT06734052 — Computer-guided Action Planning to Support Physical Activity (CAPPA) for Employees With Chronic Knee Symptoms · NA · completed
- NCT06340893 — Exercise Training in Children With Communication Impairments · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03691766 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marquette University
- Last refreshed: 26 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691766.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing